© Medneon. All Rights Reserved. Privacy Policy
OUR MISSION
Is to empower individuals and their care team with decision support tools throughout the cancer journey. The innovative Medneon digital platform combines AI and human insights with actionable information regarding an individual’s cancer risk to inform precision prevention, early detection, and management over time at the point-of-care or through telemedicine.
Company Milestones
Our timeline & how we got started
2018: Validation
- 10,000+ Patients - evaluated to identify clinical unmet needs
- JCO Publication - testing guidelines miss 50% of genetic mutations
- Prototype validated – designed by clinicians for clinicians
2019: Launch
- iGAP™ Registry – cancer and high-risk individuals over time
- Harvard NLP/AI Knowledgebase – global exclusive license of ASK2ME™
- Real-World Evidence (RWE) Platform - 10 Research sites
2020: Adoption
- Risk Tool to identify patients + Insights Tool to manage results
- 5 Life Sciences Customers – platform and data partnerships
- 200+ Providers in the network
2021: Focused Growth
- Virtual Care Network– MD + GC second opinions + e-tumor boards
- Clinical platform expansion – Genomic insights Tool
- 1000+ Providers – clinics + health systems
2022: Expansion
- Virtual Tissue Bank – biobank for precision medicine
- iGAP ™ – RWE drives federated decision support system strategy
- 2,500+ Providers – payers, employers, and direct to patient
